AI Article Synopsis
- The study aimed to assess how the use of statins and metformin affects survival rates in prostate cancer patients in Taiwan who also had hyperlipidemia and received radiotherapy.
- Among the 567 patients analyzed, those who started using statins or metformin post-diagnosis showed improved survival, with average lifespans of 9.3 and 8.1 years respectively, compared to those who used these medications before diagnosis.
- The analysis revealed that statin usage after diagnosis significantly reduced the risk of mortality, while metformin usage was linked to a higher mortality risk; overall, the findings suggest that statins may enhance survival rates for these patients.
Article Abstract
Purpose: To evaluate the association between the use of statins and/or metformin and patient survival in prostate cancer patients in Taiwan.
Subjects And Methods: Newly diagnosed prostate cancer patients who had hyperlipidemia and received radiotherapy were identified from the National Health Insurance Research Database 2000-2010. The survival rate was estimated by the Kaplan-Meier method. Univariate and multivariate Cox regression analyses were performed to examine the association of mortality. Sensitivity analysis was performed to assess the risk of mortality in patients with diabetes.
Results: The study included 567 patients. Patients who used statins or metformin after prostate cancer diagnosis had longer average survival times (9.3 years and 8.1 years, respectively; =0.001) compared with patients who persistently used or used the medicines prior to cancer diagnosis. Multivariate Cox regression analysis found that patients treated with statins after cancer diagnosis were significantly associated with a lower risk of mortality (aHR =0.24, 95% CI =0.09-0.66) compared to patients who did not use statins during the study period. Patients treated with metformin after cancer diagnosis were significantly associated more with an increased risk of mortality (aHR =6.78, 95% CI =2.45-18.77) compared to patients who did not use metformin during the study period. Sensitivity analysis revealed that the average survival time was similar among different medicine use groups in patients with diabetes.
Conclusion: The finding suggests that statins and metformin use after prostate cancer diagnosis may increase survival in patients with hyperlipidemia and radiotherapy.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6366348 | PMC |
| http://dx.doi.org/10.2147/CMAR.S166638 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The Predictive Value of tPSA, fPSA, fPSA/tPSA Combined with Ultrasound Parameters in Postoperative Gleason Grading of Prostate Cancer.
Ann Ital Chir
December 2024
Endocrine Tumor Intervention Department, Jinan Central Hospital, Central Hospital Affiliated to Shandong First Medical University, 250013 Jinan, Shandong, China.
Aim: Prostate cancer (PCa) is a common malignant tumor in men. This study aimed to explore the predictive value of serum biomarkers combined with ultrasound parameters for postoperative Gleason grading in PCa.
Methods: This study included 65 PCa patients who underwent transurethral resection of the prostate in our hospital from January 2021 to December 2023.
The number of involved regions by prostate adenocarcinoma predicts histopathology concordance between radical prostatectomy specimens and MRI/ultrasound-fusion targeted prostate biopsy.
Front Oncol
December 2024
Department of Urology, Soroka University Medical Center, Faculty of Health Sciences, Ben-Gurion University of the Negev, Be'er-Sheva, Israel.
Introduction: The prostate biopsy (PB) results should be concordant with prostatectomy histopathology to avoid overestimating or underestimating the disease, leading to inappropriate or undertreatment of prostate cancer (PCa) patients. Since the introduction of multiparametric Magnetic Resonance Imaging (mpMRI) in the diagnostic pathway of PCa, most studies have shown that MRI/Ultrasound fusion-guided (MRI-fusion) PB improves concordance with histopathology of radical prostatectomy specimens. This study aimed to evaluate the improvement in concordance of prostatectomy specimens with PB histopathology obtained using the MRI-fusion approach compared with the 12-core TRUS-Bx and to identify the variables influencing this.
View Article and Find Full Text PDFPrimary signet-ring cell carcinoma of the prostate involving the pelvis: a case report.
Front Oncol
December 2024
Department of Pathology, Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou, China.
Background: Signet-ring cell carcinoma (SRCC) originates from undifferentiated stem cells in the neck of glands within the lamina propria of the mucosa. Primarily affecting the stomach, SRCC can also involve the breast, pancreas, gallbladder, colon, and bladder, although these cases are rare. SRCC of the prostate is extremely rare, and diagnosing it pelvic puncture is particularly challenging.
View Article and Find Full Text PDFEvaluating the Diagnostic Accuracy of MRI-Derived Prostate-Specific Antigen (PSA) Density in Prostate Cancer Detection and its Association With Tumor Aggressiveness.
Cureus
November 2024
Department of Urology, Sligo University Hospital, Sligo, IRL.
Introduction Prostate-specific antigen density (PSAD), calculated by dividing serum PSA levels by prostate volume, offers greater specificity and accuracy than serum PSA alone in detecting prostate cancer (PCa). This study aimed to evaluate the diagnostic performance of PSAD in PCa detection across different PSA levels and its correlation with Gleason scores. Methods This retrospective, single-center study reviewed data from 154 patients with suspected PCa who underwent prostate MRI between July 2021 and July 2023.
View Article and Find Full Text PDFNumber of Prescription Medications and Overall Survival in Metastatic Castrate-Resistant Prostate Cancer.
Prostate Cancer
December 2024
Division of Hematology and Medical Oncology, Department of Internal Medicine, Saint Louis University School of Medicine, St. Louis, Missouri, USA.
Assessment of comorbid diseases is essential to clinical research and may risk-stratify patients for mortality independent of established methods such as the Charlson Comorbidity Index (CCI). In a retrospective study of U.S.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!